Entecavir NEW
| Price | $43 | $79 | $118 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2025-04-28 |
Product Details
| Product Name: Entecavir | CAS No.: 142217-69-4 |
| Purity: 99.72% | Supply Ability: 10g |
| Release date: 2025/04/28 |
Product Introduction
Bioactivity
| Name | Entecavir |
| Description | Entecavir (SQ34676) is a guanosine nucleoside analogue used in the treatment of chronic hepatitis B virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis B during or after therapy, but has not been linked to cases of clinically apparent liver injury. |
| Cell Research | BMS 200475 is prepared in phosphate-buffered saline (PBS) and diluted with appropriate medium containing 2% fetal bovine serum. HepG2 2.2.15 cells are plated at a density of 5×105 cells per well on 12-well Biocoat collagen-coated plates and are maintained in a confluent state for 2 to 3 days before being overlaid with 1 mL of medium spiked with BMS 200475. Quantification of HBV was performed on day 10[1]. |
| In vitro | BMS-200475 demonstrates potent antiviral activity with an EC50 of 3.75 nM against HBV by integrating into the protein primer of HBV, thereby inhibiting the priming step of the virus's reverse transcriptase. Its efficacy is notably reduced against other RNA and DNA viruses[1]. Entecavir, compared to other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine, undergoes more efficient phosphorylation to its active metabolites. Additionally, entecavir has an intracellular half-life of 15 hours[2]. |
| In vivo | Administering BMS-200475 orally on a daily basis in doses between 0.02 and 0.5 mg/kg of body weight for a duration of one to three months significantly decreases the viremia level of woodchuck hepatitis virus (WHV) in chronically infected woodchucks[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (198.36 mM), Sonication is recommended. |
| Keywords | SQ-34676 | SQ 34676 | Inhibitor | inhibit | Hepatitis B virus | HBV( HepG2 cell) | HBV | Entecavir | BMS-200475 | BMS 200475 |
| Inhibitors Related | Doxorubicin hydrochloride | Osthole | RO8191 | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Thiamine hydrochloride | 4,5-Dicaffeoylquinic acid | 4-Hydroxyacetophenone | Telbivudine | Tenofovir | Osalmid | Bifendate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-04 | ||
|
VIP5Y
|
Sinoway Industrial co., ltd.
|
2026-06-03 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-03 | ||
|
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2026-05-18 | ||
| $30.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $30.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $10.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.00 |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2026-02-02 | |
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2025-08-21 | |||
| $150.00 |
Hebei Zhuanglai Chemical Trading Co Ltd
|
2025-05-23 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY